



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Patent Examining Operations

Applicant(s): Bazin, et al.

Serial No: 09/056,072

Art Unit: 1644

Filed: April 7, 1998

Examiner: Gambel

Title: LO-CD2a Antibody and Uses Thereof for Inhibiting T-Cell Activation and Proliferation

Attorney

Docket No.: 469201-701

TRANSMITTAL LETTER

Commissioner for Patents

P.O. Box 1450

Alexandria, VA 22313-1450

SIR:

Enclosed please find the following:

1. Request for Continued Examination;
2. Terminal Disclaimer with respect to U.S. Patent No. 5,730,939;
3. Terminal Disclaimer with respect to U.S. Patent No. 5,951,983;
4. Check in the amount of \$990.00; and
5. A self-addressed, postage paid, return receipt postcard, date stamp and return of which is respectfully requested.

The Commissioner is authorized to charge payment of any additional filing fees required under 37 C.F.R. 1.16 associated with this communication or credit any overpayment to Deposit Account No. 03-0678.


FIRST CLASS CERTIFICATE

I hereby certify that this correspondence is being deposited today with the U.S. Postal Service as First Class Mail in an envelope addressed to:

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Raymond J. Lillie 2/18/04
Raymond J. Lillie, Esq. Date

Respectfully submitted,



Raymond J. Lillie, Esq.

Reg. No. 31,778

CARELLA, BYRNE, BAIN, GILFILLAN,
CECCHI, STEWART & OLSTEIN
Five Becker Farm Road
Roseland, New Jersey 07068
T: (973) 994-1700
F: (973) 994-1744



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Application of : Bazin, et al.
Serial No. : 09/056,072
Filed: April 7, 1998
For : LO-CD2a Antibody and Uses Thereof for Inhibiting
T-Cell Activation and Proliferation
Group : 1644
Examiner : Gabel

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

RECEIVED
MAY 04 2004
TECH CENTER 1600/2900

TERMINAL DISCLAIMER

Sir:

Université Catholique de Louvain, the assignee of the entire interest of the above-identified application, hereby disclaims the terminal portion of any patent granted on the above-identified application which is subsequent to the expiration date of U.S. Patent No. 5,951,983. Any patent granted on the above-identified Application shall be enforceable only for and during such period that said patent is commonly owned with U.S. Patent No. 5,951,983.

Respectfully submitted,

Raymond J. Lillie
Registration No. 31,778



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Application of : Bazin, et al.
Serial No. : 09/056,012
Filed: April 7, 1998
For : LO-CD2a Antibody and Uses Thereof for Inhibiting
T-Cell Activation and Proliferation
Group : 1644
Examiner : Gambel

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

RECEIVED

704 MAR - 1 AM 9:10

COPIES FOR
APPEALS
AND INTERFERENCES

TERMINAL DISCLAIMER

Sir:

Université Catholique de Louvain, the assignee of the entire interest of the above-identified application, hereby disclaims the terminal portion of any patent granted on the above-identified application which is subsequent to the expiration date of U.S. Patent No. 5,730,979. Any patent granted on the above-identified Application shall be enforceable only for and during such period that said patent is commonly owned with U.S. Patent No. 5,730,979.

Respectfully submitted,

Raymond J. Lillie
Registration No. 31,778